Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Exanthema 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Dapsone × Clear all
NCT01931150 2017-01-13

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
11 enrolled 7 charts
Gastrointestinal

Exanthema, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡